Numinus builds on strong MAPS Phase 3 trial results through Compassionate Access Trial of MDMA for PTSD
[embed]https://youtu.be/sCIzz2rZGCI[/embed] Yesterday, MAPS announced significant, positive results
Read More
Numinus Congratulates MAPS on Phase 3 Clinical Trial of MDMA for severe PTSD
[embed]https://www.youtube.com/watch?v=p2YxSIpuTks[/embed] 1 in 11 Canadians will suffer from PTS
Read More
Numinus Wellness’s trial for MDMA-assisted therapy is in pre-implementation stage
The study, which is in collaboration with MAPS Public Benefit Corporation (MAPS PBC), subsidiary of
Read More
Numinus Wellness Acquires Mindspace Wellbeing to Expand into Montreal
Numinus Wellness Inc. will soon have three locations in Montreal thanks to a recent acquisition.
Read More
Company with Nanaimo lab gets federal approval for psychedelic drug research
Numinus' recently amended Health Canada licence allows the company to produce and extract psilocybin
Read More
